Similarities between pathophysiological pathways leading to progression of cardiovascular and kidney diseases in human, canine and feline patients mean that SGLT2 inhibitors could provide benefits for companion animals beyond their use to control diabetes. This evidence concerns the gene SLC5A2 and kidney disorder.